PubMed Health⌕ Search

Biomedical subjects

G E Ehrlich

Publications and source records attributed to G E Ehrlich.

At least 19 recordsLinked to original sources
PubMed1992

Racemic mixtures: harmless or potentially toxic?

Issues involved in the development and evaluation of racemic drug mixtures are described. Administration of a racemic drug mixture is in reality administration of two drugs with distinct pharmacokinetic and pharmacodynamic properties. Compared with the active enantiomer, the inactive enantiomer in a racemic mixture often has different rates of absorption, metabolism, and excretion, as well as different affinities for tissue receptor and protein receptor binding sites. It may be an agonist or antagonist, produce adverse effects, increase efficacy, or place an undue burden on clearance mechanisms. Thus, the pharmacokinetic and pharmacodynamic properties, pharmacologic activity, and toxicity of each enantiomer in a racemic drug mixture need to be determined. When pharmacokinetics of enantiomers differ, the contribution of each enantiomer to effectiveness and toxicity and whether the mixture may be more beneficial than a single enantiomer will need to be considered before racemic mixtures are marketed.

Animals↗
PubMed1988

The quality of life.

Explore the source record for details and available documents.

Arthritis, Rheumatoid↗
PubMed1987

The subclinical phase of osteoarthritis.

The clinical diagnosis of osteoarthritis (OA) generally requires x-ray confirmation, fastening upon features such as narrowing of the joint and proliferative changes at the joint margins. In the formative phases, because of simple structural reasons, the joint may well not be narrowed and the proliferative changes and geodes may not as yet be apparent. Even symptomatic joint disease at this time may fail of diagnosis because the customary criteria have not yet been met. I submit that all OA is secondary, the inception being remote in time and, unless dramatic, being forgotten or never even noticed. An understanding of some of the mechanical features that characterize the progression to OA and the mechanism of pathogenesis should lead to earlier diagnosis and possible application of preventive measures.

Cartilage, Articular↗
PubMed1985

Basis and current scope of rational anti-inflammatory therapy.

With the increased understanding of inflammation today, it is clear that those therapeutic agents that control noxious effects of inflammation without blocking the protective aspects are more desirable. In the past 30 years, numerous new classes of anti-inflammatory agents have emerged, having first passed stringent clinical pharmacologic testing. Of the available nonsteroidal anti-inflammatory agents, most act through blockade of the cyclo-oxygenase pathway, and some through specific effects on the lipoxygenase pathway. Each of the major categories of nonsteroidal anti-inflammatory agents is discussed briefly with regard to these actions and their clinical effects. The use of nonsteroidal anti-inflammatory agents is also discussed in the context of the elderly patient in whom physiologic aspects of aging must be considered.

Absorption↗
PubMed1979

Rheumatology.

Explore the source record for details and available documents.

HLA Antigens↗
PubMed1978

Fungal arthritis.

Explore the source record for details and available documents.

Arthritis, Infectious↗
PubMed1978

Rheumatology.

Explore the source record for details and available documents.

Antibodies, Antinuclear↗